Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy - Top-Institutions - MDSpire

Assessment of Troponin Levels and Significant Cardiovascular Events in Patients Undergoing Immune Checkpoint Inhibitor Treatment

  • By

  • Imen Hamdi

  • Nathan El Bèze

  • Soledad Henriquez

  • Marie-Liesse Joulia

  • Raphaël Colle

  • Delphine Loirat

  • Nicolas Girard

  • Agnès Lillo Le Louet

  • Christophe Caussin

  • Mariana Mirabel

  • July 21, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Institut Montsouris
    Institut Montsouris

    Paris, France

    Key Differentiators

    • Cardiology

  • #2

    Institut Curie Paris
    Institut Curie Paris

    Paris, France

    Key Differentiators

    • Cardiology

  • #3

    Institut Curie Saint Cloud
    Institut Curie Saint Cloud

    Saint Cloud, France

    Key Differentiators

    • Cardiology

  • #4

    National Cancer Institute
    National Cancer Institute

    Bethesda, Maryland

    Key Differentiators

    • Oncology
    • Cardiology

  • #5

    Cancer Therapy Evaluation Program
    Cancer Therapy Evaluation Program

    Bethesda, Maryland

    Key Differentiators

    • Oncology

Original Source(s)

Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy

  • by Imen Hamdi, Nathan El Bèze, Soledad Henriquez, Marie-Liesse Joulia, Raphaël Colle, Delphine Loirat, Nicolas Girard, Agnès Lillo Le Louet, Christophe Caussin, Mariana Mirabel

  • July 21, 2026

Related Content

Radiomics and clinical data predict pseudoprogression after radiotherapy in high-grade glioma

Editorial: Navigating the landscape of IDH-mutant gliomas: advances in diagnosis, therapeutic management, and long-term monitoring

Vitiligo-like depigmentation following neoadjuvant chemotherapy combined with pembrolizumab in early triple-negative breast cancer: a case report